These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34722242)

  • 1. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study.
    Dai W; Qiu X; Lu C; Zou Z; Sha H; Kong W; Liu B; Du J
    Front Oncol; 2021; 11():693386. PubMed ID: 34722242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
    Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial.
    Shi Y; Zhang S; Han Q; Li J; Yan H; Lv Y; Shi H; Liu R; Dai G
    Oncotarget; 2017 Nov; 8(54):92401-92410. PubMed ID: 29190925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer.
    Rehman H; Chi J; Hakim N; Goyal SP; Olazagasti C; Jose J; Moriarty L; Saif MW
    Therap Adv Gastroenterol; 2020; 13():1756284820974912. PubMed ID: 33281939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.
    Li Z; Fan X; Jiang D; Li Q; Liu C; Wang D; Li N; Li H; Chen Z; Tang H; Lou C; Xu H; Zhan C; Dong Y; Ma Z; Wang G; Zhang C; Lu H; Zheng T; Zhang Y
    Oncologist; 2024 Nov; 29(11):997-e1614. PubMed ID: 39226089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study.
    Cheng D; Hu J; Wu X; Wang B; Chen R; Zhao W; Fang C; Ji M
    Front Oncol; 2023; 13():1281545. PubMed ID: 37965469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study.
    Chen Z; He Y; Ding C; Chen J; Gu Y; Xiao M; Li Q
    Onco Targets Ther; 2023; 16():923-935. PubMed ID: 37965584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC
    JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
    Ahn DH; Krishna K; Blazer M; Reardon J; Wei L; Wu C; Ciombor KK; Noonan AM; Mikhail S; Bekaii-Saab T
    Ther Adv Med Oncol; 2017 Feb; 9(2):75-82. PubMed ID: 28203300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
    Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
    Giannatempo P; Raggi D; Marandino L; Bandini M; Farè E; Calareso G; Colecchia M; Gallina A; Ross JS; Alessi A; Briganti A; Montorsi F; Madison R; Necchi A
    Ann Oncol; 2020 Dec; 31(12):1764-1772. PubMed ID: 32979512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
    Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
    J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
    Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J
    Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer.
    Wu K; Zhu L; Wang J; Pan K; Wang B; Li X; Yang S; Xu X; Zhang M; Li X; Chen X; Ma S; Xia B
    J Thorac Dis; 2019 Nov; 11(11):4529-4537. PubMed ID: 31903241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.